Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
MNKD · Nasdaq · United States · Pharmaceutical Preparations
In shortMANNKIND CORP is profitable.
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 11.1% | 54/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 1.7% | 27/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 10.1% | 67/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.70× | 75/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 3.59× | 12/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 2.81× | 12/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -11.89 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 3.9% | 36/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 2.33× | 100/100 |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 33.4% | 0/100 |
| Operating margin volatility | 42.8% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 51.8% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 75 | 100 | 199 | 286 | 349 |
| Cost of revenue | 17 | 16 | 21 | 17 | 27 |
| Gross profit | 59 | 84 | 178 | 268 | 322 |
| Research & development | 12 | 20 | 31 | 46 | 66 |
| Selling, general & admin | 77 | 91 | 94 | 94 | 144 |
| Operating income | (47) | (64) | 8.7 | 73 | 39 |
| Interest expense | 15 | 15 | 15 | 12 | 14 |
| Pre-tax income | (81) | (87) | (10) | 31 | 1.4 |
| Income tax | 0 | 0 | 1.6 | 2.9 | (4.5) |
| Net income | (81) | (87) | (12) | 28 | 5.9 |
| Diluted EPS | −$0.32 | −$0.34 | −$0.04 | $0.10 | $0.02 |
| Diluted shares (millions) | 249 | 257 | 267 | 284 | 314 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−11.89 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026